ArticleCancer medicine2024

Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer.

Yulian Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.